Brief: Allarity Therapeutics Says Nasdaq Hearings Panel Approved Allarity's Plan To Maintain Its Listing
11/09/2024 16:16
Sept 11 (Reuters) - Allarity Therapeutics Inc ALLR.O :
* ALLARITY THERAPEUTICS INC - AT MEETING ON AUGUST 15,
NASDAQ
HEARINGS PANEL APPROVED ALLARITY'S PLAN TO MAINTAIN ITS LISTING
* ALLARITY THERAPEUTICS - BOARD ON SEPT 3, HAS APPROVED
IMPLEMENTATION OF 1-FOR-30 REVERSE STOCK SPLIT OF ITS
OUTSTANDING SHARES OF COMMON STOCK
Source text for Eikon: ID:nGNX5K6yYP
Further company coverage: ALLR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Allarity Therapeutics
See all newsBrief: Allarity Therapeutics Announces Strategic Capital Allocation For Filing Of Spac Registration Statement
Allarity Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Allarity Therapeutics Q2 loss narrows as expenses fall
Allarity Therapeutics Inc expected to post a loss of 25 cents a share - Earnings Preview
Brief: Allarity Therapeutics Announces The Grant Of Essential U.S. Patent For Its Stenoparib Drp® Companion Diagnostic